In this online, self-learning activity:
Thalassemias are a group of recessively inherited blood disorders characterized by little or no hemoglobin production and chronic anemia of varying severity. Beta-thalassemia (BT) is most commonly found in people of Mediterranean, Middle Eastern, Asian, and North African descent. Worldwide, 1.5% of people are BT carriers, with about 40,000 infants born with BT annually. About half of patients with BT are transfusion-dependent, which may significantly impact patient quality of life. BT is caused by a point mutation in the gene encoding hemoglobin subunit beta (HBB), resulting in either lower beta-globin production (termed beta-plus [B+]) or the prevention of all beta-globin production (termed beta-zero [B0]). Disease severity depends on the extent of hemoglobin β and γ chain imbalance.
The following HCPs: hematologists; physician assistants, nurse practitioners, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who may clinically encounter patients with beta-thalassemia .
Commercial Support Disclosure: This program is supported by educational grants from Agios Pharmaceuticals and from Vertex Pharmaceuticals.
This activity is free of charge.
Release Date: April 09, 2023 -- Expiration Date: April 09, 2025
Faculty: Sherif Badawy, MD, MBBCh, MS
Introduction, faculty disclosures |
Overview of BT
o Subtype (major, intermedia, minor)
|
Management of BT
|
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
ACCME Activity #202436906
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved through content review by ScientiaCME.
Disclosure of Faculty: Sherif M. Badawy, MD, MBBCh, MS, Associate Professor of Pediatrics, Northwestern University Feinberg School of Medicine, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Agios Pharmaceuticals and Vertex Pharmaceuticals.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Strategies to prevent complications of sickle cell disease